Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of “Moderate Buy” by Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.80.

INO has been the subject of several analyst reports. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Piper Sandler assumed coverage on shares of Inovio Pharmaceuticals in a report on Wednesday, July 9th. They issued an “overweight” rating and a $5.00 price target on the stock. HC Wainwright restated a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a report on Thursday, August 14th. Finally, Zacks Research cut shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nomura Holdings Inc. bought a new position in Inovio Pharmaceuticals during the 1st quarter worth about $28,000. Catalyst Funds Management Pty Ltd bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth about $35,000. Freedom Investment Management Inc. bought a new position in Inovio Pharmaceuticals during the 1st quarter worth about $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 5,894 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in Inovio Pharmaceuticals by 221.2% during the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 27,329 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Trading Down 0.4%

Inovio Pharmaceuticals stock opened at $2.30 on Monday. The firm has a 50-day moving average price of $1.91 and a 200-day moving average price of $1.88. The firm has a market capitalization of $122.22 million, a PE ratio of -0.88 and a beta of 1.61. Inovio Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $6.70.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.02. As a group, sell-side analysts predict that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.